* 12 of 14 fda panel members say acadia provided substantial evidence of effectiveness for its drug for parkinson’s disease psychosis
The post BRIEF-FDA Panel says Acadia Parkinson’s psychosis drug has positive risk-benefit profile appeared first on NASDAQ.